Innovent, fresh from a major licensing arrangement with Takeda, reported a Phase 3 win for its Claudin18.2-directed ADC arcotatug tavatecan (IBI-343, TAK-921) in advanced gastric cancer. The company said interim results showed significant progression-free survival improvements versus investigator-selected controls, while safety and tolerability were described as favorable. The disclosure matters for the broader Takeda platform strategy because it validates earlier modality bets around ex-China and future label expansion pathways. It also underscores the intensity of CLDN18.2 competition as rivals pursue ADCs and other tumor-targeting formats. Innovent emphasized that overall survival data and full safety details are not yet provided, with the program expected to reveal additional numbers at scientific meetings or in peer-reviewed venues. Regulatory-wise, the NMPA priority-review acceptance creates near-term decision points for how fast CLDN18.2 ADCs can enter more lines of therapy in China.